Jpmorgan Chase & CO Ocugen, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding OCGN
# of Institutions
109Shares Held
66.7MCall Options Held
516KPut Options Held
272K-
Black Rock Inc. New York, NY17.9MShares$17 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.5MShares$14.7 Million0.0% of portfolio
-
State Street Corp Boston, MA14.8MShares$14 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA5.9MShares$5.61 Million0.0% of portfolio
-
Rafferty Asset Management, LLC New York, NY1.08MShares$1.02 Million0.01% of portfolio
About Ocugen, Inc.
- Ticker OCGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 216,566,000
- Market Cap $206M
- Description
- Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...